Unsurprisingly, this novel finding confirms that targeting the WDR6/UVRAG/NF‐κB/TNFα loop not only inhibits HCC progression but also produces a synergistic effect with anti‐PD‐L1 therapy. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.